A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers

Exclusion Criteria

• •1. Previous treatment with an anti-vascular endothelial growth factor (VEGF) antibody or any other antibody or protein targeting the VEGF receptor or treatment with an immunobiological drug during the last three months.
• •2. Previous history of cancer other than adequately treated basal cell or squamous cell carcinoma of the skin.
• •3. Received blood transfusions and blood donation within 3 months before screening date.
• •4. Resting blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg.
• •5. Any other severe physical incapacity.
• •6. Positive serological test for hepatitis B surface antigen or positive antibody for hepatitis C virus or positive antibody for human immunodeficiency virus (type 1 and 2).
• •7. Tuberculosis (TB) or an acute systemic infection; demonstrated by positive QuantiFERON-TB and/or Chest radiograph conducted up to 3 months prior or during the screening visit.
• •8. Major surgery planned for the study duration or cases with major surgery in the past 28 days before screening.
• •9. History of relevant drug and/or food related allergies.
• •10. History of or known hypersensitivity to bevacizumab or other recombinant human or humanized antibodies or inactive ingredients.
• •11. History of alcohol and or drug abuse/addiction.
• •12. Positive alcohol breath test and drug screen for opiates, methadone, cocaine, amphetamines, cannabinoids, barbiturates, benzodiazepines.
• •13. Strenuous exercise 96 hrs prior to admission to the clinical research center.
• •14. Any significant or acute illness within 30 days prior to the expected first dose of study drug.
• •15. Unsuitable veins for infusion and/or venepuncture.
• •16. History of bleeding disorders, thromboembolic conditions, gastrointestinal perforations or any fistulae, orthostatic hypotension, fainting spells, blackouts for any reasons; as well as presence of a non-healing wound or fracture.
• •17. Participation in another clinical study where the investigational drug was received within \< 5 x half-lives of the drug (120 days prior to screening).
• •18. Any condition or displayed behaviour that the investigator in their best clinical judgement believes could be detrimental the subject's participation in the study or result in unfavourable outcomes for the subject or study (eg. Clear signs that the patient is withholding information on their substance use/abuse status).